Michael Thase, MD

CLARITY: A Phase 2 Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

This study examined pimavanserin (PIM), a 5-HT2A receptor inverse agonist/antagonist, as a potential adjunct to SSRIs or SNRIs for major depressive disorder (MDD). Adult female and male p...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

Marlene Freeman , MD;

George Papakostas , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Srdjan Stankovic , MD, MSPH;

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019

Long-Term Treatment With Adjunctive Buprenorphine/Samidorphan Combination in Patients With Major Depressive Disorder: Interim Phase 3 Study Results

Introduction: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator demonstrating efficacy versus placebo as an adjunctive treatment for major depressive disor...

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Maurizio Fava , MD, PhD;

Asli Memisoglu , ScD;

Madhukar Trivedi , MD;

William Martin , PhD;

Michael Thase , MD;

J. Alexander Bodkin , MD;

Amy Claxton , PhD;

03/01/2019

Esketamine Nasal Spray Combined With an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression: Results of a Double-Blind, Randomized Withdrawal, Multicenter Study (SUSTAIN-1)

Background: Numerous studies have demonstrated short-term efficacy of esketamine in treatment-resistant depression (TRD), whereas long-term antidepressant effects remain to be established...

John Zajecka , MD;

Madhukar Trivedi , MD;

Andrew Winokur , MD, PhD;

Wayne Drevets , MD;

Ilona Divacka , MBA, MD;

Jaskaran Singh , MD;

Andrea Fagiolini , MD;

Wieslaw Cubala , MD, PhD;

Xiang Li , PhD;

Pierre Blier , MD, PhD;

Rosanne Lane , MD, MSc, MS;

Richard Shelton , MD;

Pilar Lim , MD, PhD;

Patricio Molero , MD, PhD;

David Hough , MD;

Husseini Manji , MD;

Istvan Bitter , MD, PhD, DSc;

Adam Janik , MD;

Michael Thase , MD;

Honglan Li , MD, PhD;

Yun Zhang , PhD;

Anna Ducca , BSN;

Ella Daly , MB, BCh, BAO;

03/01/2019

Using a Genetic Test (Combinatorial Pharmacogenomics)To Help Choose Patient-Specific Antidepressants for Depression: a Large, Blinded, Randomized Control Trial

Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...

Anthony Rothschild , MD;

Boadie Dunlop , MD;

Michael Thase , MD;

Charles Conway , MD;

Richard Shelton , MD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Francis Mondimore , MD;

Krystal Brown , PhD;

Matthew Macaluso , DO;

Michael Jablonski , PhD;

Alexa Gilbert , MSc, MBA;

Bryan Dechairo , PhD;

Lindsey Burns , MBA;

Charles DeBattista , MD;

Sagar Parikh , MD;

John Greden , MD;

03/01/2019

Patient-Reported Effects of Adjunctive Brexpiprazole on Calming and Engagement in Major Depressive Disorder: Post Hoc Analysis of Clinical Trial Exit Interviews

Background: Calming patients (without sedation) and increasing engagement (without overactivation) are important components of the successful treatment of major depressive disorder (MDD)....

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Catherine Gupta , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

T. Michelle Brown , PhD;

10/08/2020

A Buprenorphine-Samidorphan Combination (BUP/SAM) for Adjunctive Treatment of Major Depressive Disorder: Results From Analyses of US Patients From Three Placebo-Controlled Trials

Background: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator for adjunctive treatment of major depressive disorder. To account for differences in treatmen...

William Martin , PhD;

Elliot Ehrich , MD;

Michael Thase , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Amy Claxton , PhD;

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Asli Memisoglu , ScD;

02/28/2019

Effect of Adjunctive Pimavanserin on Insomnia and Function in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY

Up to 90% of patients with major depressive disorder (MDD) experience sleep disturbances. CLARITY was a phase 2 study of adjunctive pimavanserin, a 5-hydroxytryptamine2A antagonist/invers...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

Manish Jha ;

Maurizio Fava , MD, PhD;

Marlene Freeman , MD;

Madhukar Trivedi , MD;

George Papakostas , MD;

Srdjan Stankovic , MD, MSPH;

10/08/2020

Efficacy of Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Partial Response to Antidepressant Treatment: a Post Hoc Analysis of Three Randomized Studies

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT), which are associated wit...

Michael Thase , MD;

Liz Kelly ;

01/19/2023

Efficacy of Adjunctive Brexpiprazole in Adults With MDD: Improvement of Patient Engagement Based on Selected Items From the Inventory of Depressive Symptomatology Self-Report (IDS-SR) Scale

Objective: These post-hoc analyses used relevant items from the IDS-SR to explore whether treatment with adjunctive brexpiprazole in patients with MDD has potential to improve a new conce...

Anne Pedersen , MSc;

Klaus Groes Larsen , PhD;

Anna-Greta Nylander , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Roger McIntyre , MD, FRCPC;

11/22/2019